Does Rybelsus cause hair loss? This is a question increasingly raised by patients taking oral semaglutide for type 2 diabetes in the UK. Rybelsus is a GLP-1 receptor agonist that works by stimulating insulin secretion, suppressing glucagon, and slowing gastric emptying. Whilst hair loss is not listed as a recognised adverse effect in Rybelsus's approved Summary of Product Characteristics, some patients have reported shedding during treatment. Understanding the evidence, the likely mechanisms, and when to seek medical advice is essential for anyone concerned about hair changes whilst taking this medicine.

Hair Loss and Rybelsus: What the Evidence Shows

Hair loss is not listed as a recognised adverse effect in the Rybelsus SmPC, and the MHRA has not formally identified it as a confirmed adverse reaction to oral semaglutide; reported cases are more plausibly linked to weight-loss-related telogen effluvium.

Rybelsus (oral semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the management of type 2 diabetes mellitus in adults. It is not licensed for weight management in the UK. It works by mimicking the action of the naturally occurring GLP-1 hormone, stimulating insulin secretion, suppressing glucagon release, and slowing gastric emptying. As its use has grown, some patients have reported experiencing hair thinning or shedding during treatment, prompting questions about whether Rybelsus directly causes hair loss.

Currently, hair loss is not listed as a recognised adverse effect of Rybelsus in its Summary of Product Characteristics (SmPC), as published on the Electronic Medicines Compendium (emc) and assessed by the European Medicines Agency (EMA) in its European Public Assessment Report (EPAR). The Medicines and Healthcare products Regulatory Agency (MHRA) has not formally identified hair loss as a confirmed adverse reaction to oral semaglutide in its post-marketing communications.

However, hair loss — specifically a condition known as telogen effluvium — has been reported in post-marketing spontaneous reports associated with injectable semaglutide (Ozempic and Wegovy), particularly in the context of significant or rapid weight loss. Whether alopecia is formally listed in the UK/EU SmPCs for injectable semaglutide formulations should be verified against the current emc entries for those products, as product information is subject to update. It is plausible that similar experiences may occur with the oral formulation, though no confirmed causal link has been established.

It is important to approach this topic with balance. Post-marketing spontaneous reports suggest a possible association, but association does not confirm causation. Many individuals taking Rybelsus are also managing other health conditions, dietary changes, or concurrent medications — all of which can independently contribute to hair changes. Understanding the broader clinical picture is essential before attributing hair loss solely to Rybelsus.

How Semaglutide May Affect Hair Growth Cycles

The most plausible mechanism is indirect: significant or rapid weight loss caused by appetite suppression can trigger telogen effluvium, shifting hair follicles prematurely into the resting phase and causing diffuse shedding two to four months later.

To understand why hair loss might occur during semaglutide treatment, it helps to understand the normal hair growth cycle. Hair follicles cycle through three phases: anagen (active growth), catagen (transition), and telogen (resting and shedding). Under normal circumstances, approximately 85–90% of hairs are in the anagen phase at any given time. When the body experiences significant physiological stress — such as rapid weight loss, nutritional deficiency, or metabolic change — a disproportionate number of follicles can shift prematurely into the telogen phase, resulting in diffuse shedding typically two to four months later. This is known as telogen effluvium, and is well described in UK clinical resources including guidance from the British Association of Dermatologists (BAD) and the Primary Care Dermatology Society (PCDS).

Semaglutide, including the oral form Rybelsus, promotes weight loss partly through appetite suppression and reduced caloric intake. If weight loss is substantial or occurs rapidly, the body may interpret this as a physiological stressor, potentially triggering telogen effluvium. This mechanism is not unique to semaglutide — it has been observed with other weight-loss interventions, including bariatric surgery and very low-calorie diets. The PIONEER clinical trial programme, which evaluated oral semaglutide across multiple doses and patient populations (summarised in the EMA EPAR for Rybelsus), demonstrated meaningful weight reduction, which is the context in which hair changes are most plausibly explained.

Additionally, GLP-1 receptors are present in various tissues throughout the body, including the skin. Some researchers have speculated that direct receptor activity in hair follicle tissue could theoretically influence follicular cycling; however, robust clinical evidence to support this specific mechanism in humans is currently lacking, and this remains speculative. At present, the most plausible explanation for hair changes during Rybelsus treatment remains the indirect effect of weight loss and potential nutritional shifts rather than a direct pharmacological action on hair follicles.

Other Factors That Can Cause Hair Loss During Treatment

Nutritional deficiencies, thyroid dysfunction, androgenetic alopecia, psychological stress, and concurrent medications such as metformin or beta-blockers can all independently contribute to hair loss and must be considered before attributing shedding solely to Rybelsus.

When a patient notices hair loss whilst taking Rybelsus, it is clinically important to consider the full range of potential contributing factors rather than assuming the medication is solely responsible. Several conditions and circumstances commonly associated with hair loss may coincide with the period of starting or continuing treatment:

• Nutritional deficiencies: Reduced appetite and lower food intake can lead to insufficient levels of iron, zinc, biotin, and protein — all of which are important for healthy hair growth. These deficiencies are a well-recognised cause of telogen effluvium. However, investigations and any supplementation should be guided by clinical assessment and confirmed deficiency, rather than undertaken routinely.

• Thyroid dysfunction: Both hypothyroidism and hyperthyroidism are associated with diffuse hair thinning. Thyroid disorders are also more prevalent in people with type 2 diabetes, making this an important differential to consider where clinically indicated.

• Androgenetic alopecia: This is the most common form of hair loss in both men and women and may become more noticeable during periods of metabolic or hormonal change.

• Stress and psychological factors: The psychological impact of managing a chronic condition, adjusting to lifestyle changes, or experiencing side effects such as nausea can itself act as a trigger for stress-related hair shedding.

• Other medications: Concurrent use of medicines such as metformin (which can impair vitamin B12 absorption with long-term use), certain antihypertensives (for example, beta-blockers), or other agents may occasionally contribute to hair changes, though drug-induced alopecia from these medicines is generally uncommon. The BNF provides further detail on medicines associated with hair loss.

A targeted medication review and appropriate blood tests — selected on the basis of clinical history and examination — are therefore important when evaluating hair loss in any patient taking Rybelsus, ensuring that treatable underlying causes are not overlooked. It is also worth noting that biotin (vitamin B7) supplements can interfere with a range of laboratory assays, potentially causing falsely abnormal results; the MHRA has issued a Drug Safety Update on this. Patients should inform their GP or practice nurse if they are taking biotin supplements before having blood tests.

What MHRA and Clinical Trial Data Report

PIONEER trial data did not identify hair loss as a statistically significant adverse event for oral semaglutide, and the MHRA has not formally recognised it as an adverse reaction; post-marketing reports for injectable semaglutide suggest a possible association, but causality remains unconfirmed.

The MHRA is the UK regulatory authority responsible for monitoring the safety of medicines, including post-marketing surveillance through the Yellow Card scheme. As of currently available data, hair loss has not been formally identified as a recognised adverse effect of oral semaglutide (Rybelsus) in MHRA communications or in the product's approved SmPC (available on the emc).

In the pivotal PIONEER clinical trial programme, which evaluated oral semaglutide across multiple doses and patient populations (summarised in the EMA EPAR for Rybelsus), hair loss was not reported as a statistically significant adverse event. However, clinical trials are not always powered to detect less common or subjectively reported side effects, and post-marketing experience often reveals a broader safety profile than trials alone can capture.

For injectable semaglutide formulations, post-marketing spontaneous reports of hair loss have been received. Patients and healthcare professionals should consult the current UK SmPCs for Ozempic and Wegovy (available on the emc) and the relevant EMA EPARs for the most up-to-date information on whether alopecia is formally listed as an adverse reaction in UK/EU product information, as labelling may be updated over time. Where formal regulatory recognition is absent, the available evidence points more towards weight-loss-related telogen effluvium as the most likely explanation, rather than a direct drug effect — though causality has not been definitively excluded.

Patients and healthcare professionals are encouraged to report any suspected adverse reactions — including hair loss — to the MHRA via the Yellow Card scheme (yellowcard.mhra.gov.uk). This ongoing pharmacovigilance is vital for building a clearer evidence base and ensuring patient safety as the use of GLP-1 receptor agonists continues to expand in the UK.

When to Speak to Your GP or Prescriber

Seek GP advice if hair loss is significant, rapidly worsening, patchy, accompanied by scalp symptoms, or associated with fatigue or other systemic symptoms; do not stop Rybelsus without medical guidance as this may affect blood glucose control.

Whilst some degree of hair shedding during weight loss or metabolic change can be a temporary and self-limiting process, there are circumstances in which it is important to seek professional advice. You should contact your GP or prescriber if you notice any of the following:

• Significant or rapidly worsening hair loss that is causing distress or affecting quality of life

• Patchy hair loss (which may suggest alopecia areata, an autoimmune condition requiring separate assessment)

• Signs that may suggest scarring alopecia, such as pain, redness, scaling, or itching of the scalp, or loss of eyebrows or eyelashes — these warrant prompt dermatology referral

• Hair loss accompanied by other symptoms, such as fatigue, cold intolerance, unexpected weight changes, or skin changes — which could indicate an underlying thyroid or nutritional disorder

• Hair loss that begins several months after starting Rybelsus, which may be consistent with telogen effluvium and warrants clinical assessment

• Concerns about nutritional adequacy, particularly if appetite has been significantly reduced or dietary variety has become limited

Your GP can arrange relevant blood tests where clinically indicated — for example, ferritin (particularly in women with heavy menstrual bleeding), thyroid function, full blood count, and vitamin B12 (especially if you are taking metformin long-term or have relevant symptoms). Tests are selected based on your individual history and examination findings, rather than as a routine panel for everyone. If you take biotin supplements, let your GP or practice nurse know before having blood tests, as biotin can interfere with certain laboratory assays (MHRA Drug Safety Update).

It is equally important not to stop Rybelsus without medical advice, as discontinuing treatment abruptly may affect blood glucose management. Your prescriber can help weigh the benefits and risks and explore whether any adjustments to your treatment plan are appropriate. NHS guidance on hair loss (alopecia) provides further information on when to seek help.

Managing Hair Loss Whilst Taking Rybelsus

Hair shedding associated with weight loss typically resolves within six to twelve months; key management steps include ensuring adequate protein, iron, and micronutrient intake, avoiding rapid weight loss, and seeking GP or dermatology review for severe or persistent cases.

For most people who experience hair shedding in association with Rybelsus or weight loss, the condition is temporary and tends to resolve within six to twelve months once the body adapts to its new weight and nutritional status stabilises, as described in BAD and PCDS guidance on telogen effluvium. However, there are several practical steps that may help support hair health during this period.

Nutritional support is a key priority. Working with your GP or a registered dietitian to ensure adequate intake of:

• Protein (from lean meats, fish, eggs, legumes, or dairy)

• Iron and ferritin (particularly important for women; low ferritin is a common and treatable cause of hair shedding)

• Zinc, B vitamins, and biotin (best obtained from a varied, balanced diet; supplementation should only be considered if a deficiency has been confirmed by blood tests, as unnecessary supplementation is not recommended and biotin supplements can interfere with laboratory assays — see MHRA Drug Safety Update)

Avoiding excessively rapid weight loss can also reduce physiological stress on hair follicles. NICE and NHS guidance on weight management emphasises a gradual, sustainable approach, which is broadly consistent with minimising the risk of telogen effluvium.

From a hair care perspective, gentle handling — avoiding tight hairstyles, excessive heat styling, and harsh chemical treatments — can help reduce additional mechanical stress on already vulnerable follicles.

Topical minoxidil is available over the counter in the UK and is licensed for androgenetic alopecia (pattern hair loss). Its use in telogen effluvium is off-label and should be discussed with a GP or dermatologist before starting, who can advise whether it is appropriate in your individual circumstances.

For severe, prolonged, or unexplained hair loss, referral to an NHS dermatologist is the recommended pathway. If you are considering consulting a trichologist privately, please be aware that trichology is not a statutorily regulated healthcare profession in the UK, and a dermatology opinion should be sought for any clinically significant or persistent hair loss. If hair loss is causing significant psychological distress, it is entirely appropriate to discuss this with your healthcare team.

Frequently Asked Questions